Purpose TNFerade biologic is a novel means of delivering tumor necrosis factor alpha to
tumor cells by gene transfer. We herein report final results of the largest randomized phase …

BACKGROUND: TNFeradeBiologic (AdGVEGR. TNF. 11D) is a replication-deficient
adenoviral vector that expresses tumor necrosis factor-α (TNF-α) under the control of the Egr …

Pancreatic adenocarcinoma is an aggressive and highly lethal malignancy. Currently,
gemcitabine is commonly used in patients with pancreatic cancer. However, the life …

Although FOLFIRINOX significantly increases survival in metastatic pancreatic cancer (MPC)
compared to gemcitabine (Conroy et al. N Engl J Med 364: 1817–1825, 2011), toxicities …

Background 35% of patients with pancreatic cancer have unresectable locally advanced
disease at diagnosis. Several studies have examined systemic chemotherapy with …

Aim We compared the efficacy of modified 5-fluorouracil, leucovorin, irinotecan, and
oxaliplatin (mFOLFIRINOX) with that of gemcitabine plus nab-paclitaxel (GnP) for locally …

The objective of our retrospective institutional experience is to report the overall response
rate, R0 resection rate, progression‐free survival, and safety/toxicity of neoadjuvant …

Purpose The purpose of the present study was to evaluate the activity and the tolerability of
the FOLFIRI regimen, administered as second-line chemotherapy in patients with locally …

Objectives FOLFIRINOX (5-fluorouracil [5-FU], oxaliplatin, and irinotecan) as compared with
gemcitabine in pancreatic cancer (PC) has superior activity and increased toxicity. The bolus …

Background We conducted a multicentre phase II trial to investigate feasibility and antitumor
activity of sequential FOLFIRINOX and Stereotactic Body Radiotherapy (SBRT) in patients …